Small molecule · Inhibitor of hepatocyte growth factor receptor (c-Met) (MET), vascular endothelial growth factor receptor 2 (VEGFR2) (KDR) and AXL receptor tyrosine kinase (AXL) · developed by Exelixis
Zanzalintinib is an orally bioavailable inhibitor of the receptor tyrosine kinases c-Met, VEGFR2, AXL and MER, binding these receptors and blocking their kinase activity. It is being studied in renal cell carcinoma and other advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06943755 | Phase 2/3 | Pancreatic Neuroendocrine Tumor (pNET) | Recruiting | EXEL |
| NCT05678673 | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | Active not recruiting | EXEL |
| NCT06191796 | Phase 1 | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | Terminated | RCUS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non-Clear Cell Renal Cell CarcinomaRenal Cell Carcinoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the EXEL page.
See EXEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EXEL catalysts and pipeline →